These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6331440)

  • 1. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26.
    Minocha A; Long BH
    Biochem Biophys Res Commun; 1984 Jul; 122(1):165-70. PubMed ID: 6331440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.
    Long BH; Musial ST; Brattain MG
    Biochemistry; 1984 Mar; 23(6):1183-8. PubMed ID: 6712942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
    Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
    Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems.
    Gupta RS; Bromke A; Bryant DW; Gupta R; Singh B; McCalla DR
    Mutagenesis; 1987 May; 2(3):179-86. PubMed ID: 3325741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners.
    Long BH; Stringfellow DA
    Adv Enzyme Regul; 1988; 27():223-56. PubMed ID: 2854948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of VM26, a specific inhibitor of type II DNA topoisomerase, on SV40 chromatin replication in vitro.
    Richter A; Strausfeld U
    Nucleic Acids Res; 1988 Nov; 16(21):10119-29. PubMed ID: 2848217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.
    Issell BF; Tihon C; Curry ME
    Cancer Chemother Pharmacol; 1982; 7(2-3):113-5. PubMed ID: 7083450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the DNA topoisomerase II inhibitor, VM26, on transcriptional initiation in vitro.
    Preston GM; White BA
    Life Sci; 1990; 46(18):1309-18. PubMed ID: 2161065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
    Kerrigan D; Pommier Y; Kohn KW
    NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of VM26 (teniposide), a specific inhibitor of type II DNA topoisomerase, on SV40 DNA replication in vivo.
    Richter A; Strausfeld U; Knippers R
    Nucleic Acids Res; 1987 Apr; 15(8):3455-68. PubMed ID: 3033604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M; Harada T; Tanaka T; Kuwano M
    Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
    Chen GL; Yang L; Rowe TC; Halligan BD; Tewey KM; Liu LF
    J Biol Chem; 1984 Nov; 259(21):13560-6. PubMed ID: 6092381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships among glycosidic derivatives of 4'-demethylepipodophyllotoxin and epipodophyllotoxin, showing VM26- and VP16-213-like activities.
    Gupta RS; Chenchaiah PC; Gupta R
    Anticancer Drug Des; 1987 Aug; 2(1):1-12. PubMed ID: 3449081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase I and II cleavage of adenovirus DNA in vivo: both topoisomerase activities appear to be required for adenovirus DNA replication.
    Schaack J; Schedl P; Shenk T
    J Virol; 1990 Jan; 64(1):78-85. PubMed ID: 2152835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16).
    Long BH
    Semin Oncol; 1992 Apr; 19(2 Suppl 6):3-19. PubMed ID: 1329225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The podophyllotoxin derivatives VP16-213 and VM26.
    Issell BF
    Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization.
    Gewirtz DA; Ellis AL; Randolph JK; Yanovich S; Swerdlow PS; Povirk LF; Yalowich JC
    Cancer Commun; 1989; 1(3):175-80. PubMed ID: 2561738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function.
    Schaak J; Schedl P; Shenk T
    Nucleic Acids Res; 1990 Mar; 18(6):1499-508. PubMed ID: 2158079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.